欢迎登录材料期刊网

材料期刊网

高级检索

以1,2-丙二胺为起始原料,经手性拆分得到R-(-)-1,2-丙二胺,再同氯亚铂酸钾、碘化钾、硝酸银、1,3-丙二酸钠等物质反应,制成((R)-(-)-1,2-丙二胺)(1,3-丙二酸)合铂(II),通过元素分析、红外光谱、核磁共振等对其进行化恘结构确证,结果表明所合成产品同理论一致,并进行初步体外活性评价,表明该化合物对于肺癌A-549及白血病HL-60肿瘤细胞有一定活性。

(R)-(-)-1,2diaminepropane was obtained by rotation resolution of 1,2-diaminepropane as the starting material, and then was reacted with potassium tetrachloroplatinate, potassium iodide, silver nitrate, sodium 1,3-malonate to produce ((R)-(-)-1,2-diaminepropane)(1,3-malonate) platinum(II). Elemental analysis, infrared and nuclear magnetic resonance were used to characterize its chemical structure. Preliminary in vitro anticancer test showed that the complex was active against A-549 and HL-60 cancer cell line.

参考文献

[1] Boretti A;Leone R;Muggia F M.Platinum and Other Heavy Metal Compound in Cancer Chemotherapy Molecular Mechanisms and Clinical Application[M].Humana Press,2012
[2] 陈亿新,刘天穗,刘汝锋,李国良,李月明,曾志.手性药物技术与展望[J].广州大学学报(自然科学版),2002(01):39-43.
[3] Testa B .Mechanism of chiral recognition in xenobiotic metabolism and drug receptor interactions[J].Chirality,1989,1(01):7-9.
[4] Yokoo S;Masuda S;Yonezawa A;Terada T;Katsura T;Inui K .Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.[J].Drug Metabolism and Disposition: The Biological Fate of Chemicals,2008(11):2299-2306.
[5] Lee JW;Park JK;Lee SH;Kim SY;Cho YB;Kuh HJ .Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.[J].Anti-cancer drugs,2006(4):377-384.
[6] Hilgard P;Voegeli R;Zechel H J et al.Characterization of D-19466 a new platinum complex with anticancer efficacy[J].Journal of Cancer Research and Clinical Oncology,1990,116(z1):1(427).
[7] 朱泽兵,金全,怿红花,普绍平,王庆琨,李学杰,温志寿,王蒙.顺式-水杨酸-(反式-(-)-1,2-环己二胺)合铂(II)的合成、表征及抗肿瘤活性[J].贵金属,2014(01):56-58,62.
[8] 朱泽兵,王庆琨,徐红花,普绍平,丛艳伟,贝玉祥,黄天俊,缪祥宏.顺式-甲基丙二酸-二氨合铂(II)的合成、表征及抗癌活性[J].贵金属,2013(04):40-42.
上一张 下一张
上一张 下一张
计量
  • 下载量()
  • 访问量()
文章评分
  • 您的评分:
  • 1
    0%
  • 2
    0%
  • 3
    0%
  • 4
    0%
  • 5
    0%